Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Express Scripts
McKinsey
Boehringer Ingelheim
AstraZeneca

Last Updated: January 27, 2023

Investigational Drug Information for Seviteronel


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Seviteronel?

Seviteronel is an investigational drug.

There have been 6 clinical trials for Seviteronel. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2015.

The most common disease conditions in clinical trials are Triple Negative Breast Neoplasms, Prostatic Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Innocrin Pharmaceutical, St Vincent's Hospital, Sydney, and National Cancer Institute (NCI).

Recent Clinical Trials for Seviteronel
TitleSponsorPhase
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast CancerSt Vincent's Hospital, SydneyPhase 1/Phase 2
Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive GlioblastomaSt Vincent's Hospital, SydneyPhase 2
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)Innocrin PharmaceuticalPhase 1/Phase 2

See all Seviteronel clinical trials

Clinical Trial Summary for Seviteronel

Top disease conditions for Seviteronel
Top clinical trial sponsors for Seviteronel

See all Seviteronel clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Express Scripts
McKinsey
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.